Re: Latest upgrade on GBT:
(Adding a little more detail here - From Bret Jensen blog)
https://seekingalpha.com/instablog/498952-bret-jensen/5266984-4-analyst-calls-open-new-trading-week
"Finally, H.C. Wainwright maintains its Buy rating and $150 price target on Global Blood Therapeutics (GBT) today. Here are the details of their valuation calculation.
Our Buy rating and $150 are based on a DCF analysis, derived using a beta of 1.40, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2024. We estimate approximately 70K patients in U.S., 42K patients in the $60K (increased from $75K and $50K) U.S. and EU launch prices, respectively, a 2020 commercial launch, 70% compliance, and 23% gross-to-net.”